CTX-10726
CTX-10726-001
Phase 1 small_molecule active
Quick answer
CTX-10726 for Gastroesophageal Cancer (GC) is a Phase 1 program (small_molecule) at Compass Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Compass Therapeutics
- Indication
- Gastroesophageal Cancer (GC)
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active